265 related articles for article (PubMed ID: 18579112)
41. Reduced exposure to calcineurin inhibitors in renal transplantation.
Ekberg H; Tedesco-Silva H; Demirbas A; Vítko S; Nashan B; Gürkan A; Margreiter R; Hugo C; Grinyó JM; Frei U; Vanrenterghem Y; Daloze P; Halloran PF;
N Engl J Med; 2007 Dec; 357(25):2562-75. PubMed ID: 18094377
[TBL] [Abstract][Full Text] [Related]
42. Mycophenolate mofetil for the treatment of uveitis.
Teoh SC; Hogan AC; Dick AD; Lee RW
Am J Ophthalmol; 2008 Nov; 146(5):752-60, 760.e1-3. PubMed ID: 18455143
[TBL] [Abstract][Full Text] [Related]
43. Is complete avoidance of calcineurin inhibitors or steroids now possible? Importance of patient selection and choice of regimen.
Vincenti F
Transplant Proc; 2001 Jun; 33(4 Suppl):11S-18S. PubMed ID: 11406263
[No Abstract] [Full Text] [Related]
44. General principles for the treatment of non-infectious uveitis.
Díaz-Llopis M; Gallego-Pinazo R; García-Delpech S; Salom-Alonso D
Inflamm Allergy Drug Targets; 2009 Sep; 8(4):260-5. PubMed ID: 19754409
[TBL] [Abstract][Full Text] [Related]
45. Daclizumab: novel biologic immunoprophylaxis for prevention of acute rejection in renal transplantation.
Vincenti F
Transplant Proc; 1999 Sep; 31(6):2206-7. PubMed ID: 10500546
[No Abstract] [Full Text] [Related]
46. [Recurrent uveitis and therapy with monoclonal antibody (daclizumab)].
Hernández Garfella ML; Díaz Llopis M; Salom Alonso D; Cervera Taulet E
Arch Soc Esp Oftalmol; 2004 Dec; 79(12):593-8. PubMed ID: 15627927
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial.
Yoshida EM; Marotta PJ; Greig PD; Kneteman NM; Marleau D; Cantarovich M; Peltekian KM; Lilly LB; Scudamore CH; Bain VG; Wall WJ; Roy A; Balshaw RF; Barkun JS
Liver Transpl; 2005 Sep; 11(9):1064-72. PubMed ID: 16123958
[TBL] [Abstract][Full Text] [Related]
48. Comparison of basiliximab and daclizumab with triple immunosuppression in renal transplantation.
Aktas S; Colak T; Baskin E; Sevmis S; Ozdemir H; Moray G; Karakayali H; Haberal M
Transplant Proc; 2011 Mar; 43(2):453-7. PubMed ID: 21440732
[TBL] [Abstract][Full Text] [Related]
49. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.
Galor A; Perez VL; Hammel JP; Lowder CY
Ophthalmology; 2006 Dec; 113(12):2317-23. PubMed ID: 16996615
[TBL] [Abstract][Full Text] [Related]
50. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation.
Nelson DR; Soldevila-Pico C; Reed A; Abdelmalek MF; Hemming AW; Van der Werf WJ; Howard R; Davis GL
Liver Transpl; 2001 Dec; 7(12):1064-70. PubMed ID: 11753908
[TBL] [Abstract][Full Text] [Related]
51. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation.
Rostaing L; Cantarovich D; Mourad G; Budde K; Rigotti P; Mariat C; Margreiter R; Capdevilla L; Lang P; Vialtel P; Ortuño-Mirete J; Charpentier B; Legendre C; Sanchez-Plumed J; Oppenheimer F; Kessler M;
Transplantation; 2005 Apr; 79(7):807-14. PubMed ID: 15818323
[TBL] [Abstract][Full Text] [Related]
52. A prospective randomized open study in liver transplant recipients: daclizumab, mycophenolate mofetil, and tacrolimus versus tacrolimus and steroids.
Otero A; Varo E; de Urbina JO; Martín-Vivaldi R; Cuervas-Mons V; González-Pinto I; Rimola A; Bernardos A; Otero S; Maldonado J; Herrero JI; Barrao E; Domínguez-Granados R
Liver Transpl; 2009 Nov; 15(11):1542-52. PubMed ID: 19877219
[TBL] [Abstract][Full Text] [Related]
53. Retention time for corticosteroid-sparing systemic immunosuppressive agents in patients with inflammatory eye disease.
Baker KB; Spurrier NJ; Watkins AS; Smith JR; Rosenbaum JT
Br J Ophthalmol; 2006 Dec; 90(12):1481-5. PubMed ID: 16914474
[TBL] [Abstract][Full Text] [Related]
54. From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies.
Hugh J; Van Voorhees AS; Nijhawan RI; Bagel J; Lebwohl M; Blauvelt A; Hsu S; Weinberg JM
J Am Acad Dermatol; 2014 Jan; 70(1):168-77. PubMed ID: 24184141
[TBL] [Abstract][Full Text] [Related]
55. Immunosuppression with low-dose daclizumab in liver transplant recipients with impaired kidney function: a single-center experience.
Post M; Raszeja-Wyszomirska J; Jarosz K; Lubikowski J; Wasilewicz M; Mydłowska M; Milkiewicz P; Wójcicki M
Transplant Proc; 2009 Oct; 41(8):3107-9. PubMed ID: 19857687
[TBL] [Abstract][Full Text] [Related]
56. Tumor necrosis factor inhibitors in patients with Takayasu arteritis: experience from a referral center with long-term followup.
Schmidt J; Kermani TA; Bacani AK; Crowson CS; Matteson EL; Warrington KJ
Arthritis Care Res (Hoboken); 2012 Jul; 64(7):1079-83. PubMed ID: 22328491
[TBL] [Abstract][Full Text] [Related]
57. Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials.
Lorenzetti R; Zullo A; Ridola L; Diamanti AP; Laganà B; Gatta L; Migliore A; Armuzzi A; Hassan C; Bruzzese V
Ann Med; 2014 Nov; 46(7):547-54. PubMed ID: 25105206
[TBL] [Abstract][Full Text] [Related]
58. [Uveitic macular edema and the pharmacotherapy].
Liu X; Zhang M
Zhonghua Yan Ke Za Zhi; 2015 Feb; 51(2):151-4. PubMed ID: 25908007
[TBL] [Abstract][Full Text] [Related]
59. Maintenance immunosuppression with intermittent intravenous IL-2 receptor antibody therapy in renal transplant recipients.
Gabardi S; Catella J; Martin ST; Perrone R; Chandraker A; Magee CC; McDevitt-Potter LM
Ann Pharmacother; 2011 Sep; 45(9):e48. PubMed ID: 21811001
[TBL] [Abstract][Full Text] [Related]
60. The safety and efficacy of noncorticosteroid triple immunosuppressive therapy in the treatment of refractory chronic noninfectious uveitis in childhood.
Little JA; Sen ES; Strike H; Hinchcliffe A; Guly CM; Lee RW; Dick AD; Ramanan AV
J Rheumatol; 2014 Jan; 41(1):136-9. PubMed ID: 24085549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
